Shares in Puma Biotechnology jumped 40% after the FDA trod lightly around doubts about its filing for approval of breast cancer drug neratinib. But the talking points raised ahead of Wednesday’s ...
PUMA (XTRA:PUM) has quietly staged a sharp rebound, with the share price jumping about 34% over the past month and 12% in the past 3 months, despite still weak one year returns. See our latest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results